Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 2/20 | 0.40 |
| ▸ | KDM1A | O60341 | 4/20 | 0.35 |
| ▸ | KDM1B | Q8NB78 | 2/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2841151 | 0.86 | RAPGEF4 (0.34) | RAPGEF4KDM1AKDM1BPTGS1PTGS2 | |
| SCHEMBL919665 | 0.80 | KDM1A (0.42) | RAPGEF4KDM1AKDM1BALDH1A1CES2 | |
| SCHEMBL29863733 | 0.79 | RAPGEF4 (0.40) | RAPGEF4KDM1AKDM1B | |
| SCHEMBL13550059 | 0.79 | NQO2 (0.32) | KDM1AKDM1BACHE | |
| SCHEMBL2226316 | 0.79 | APEX1 (0.35) | RAPGEF4KDM1AKDM1BPTGS1PTGS2 | |
| SCHEMBL29664557 | 0.79 | NQO2 (0.32) | KDM1AKDM1BACHE | |
| SCHEMBL1043169 | 0.79 | RAPGEF4 (0.40) | RAPGEF4KDM1AKDM1B | |
| SCHEMBL6553272 | 0.77 | KDM1A (0.41) | RAPGEF4KDM1AKDM1BALDH1A1CES2 | |
| SCHEMBL24724647 | 0.75 | PTGS1 (0.38) | PTGS1PTGS2ALDH1A1 | |
| SCHEMBL13550060 | 0.75 | RAPGEF4 (0.32) | RAPGEF4SMN1; SMN2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159508-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2023-05-25 | — | — | US | disclosed |
| US-20230103791-A1 | 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-04-06 | — | — | US | disclosed |
| EP-3134411-B1 | PURINE DERIVATIVES AS CD73 INHIBITORS FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INT (DE) | 2021-06-30 | — | — | EP | disclosed |
| US-10844044-B2 | WDR5 inhibitors and modulators | VANDERBILT UNIVERSITY (US) | 2020-11-24 | — | — | US | disclosed |
| US-10654884-B2 | Purine derivatives as CD73 inhibitors for the treatment of cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-05-19 | — | — | US | disclosed |
| US-20200102288-A1 | WDR5 INHIBITORS AND MODULATORS | VANDERBILT UNIVERSITY | 2020-04-02 | — | — | US | disclosed |
| EP-3134411-A1 | PURINE DERIVATIVES AS CD73 INHIBITORS FOR THE TREATMENT OF CANCER | Vitae Pharmaceuticals, Inc. (US) | 2017-03-01 | — | — | EP | disclosed |
| US-20170044203-A1 | PURINE DERIVATIVES AS CD73 INHIBITORS FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-02-16 | — | — | US | disclosed |
| WO-2015164573-A1 | PURINE DERIVATIVES AS CD73 INHIBITORS FOR THE TREATMENT OF CANCER | VITAE PHARMACEUTICALS, INC. (US) | 2015-10-29 | — | — | WO | disclosed |
| US-20100010058-A1 | Azoline Compounds for Combating Arthropod Pests | BASF SE (DE) | 2010-01-14 | — | — | US | disclosed |
| US-20080312085-A1 | Pesticidal Compositions | BASF SE (DE) | 2008-12-18 | — | — | US | disclosed |
| US-20080312085-A1 | Pesticidal Compositions | BASF SE (DE) | 2008-12-18 | — | — | US | disclosed |
| WO-2007147701-A1 | AZOLINE COMPOUNDS FOR COMBATING ARTHROPOD PESTS | BASF SE (DE) | 2007-12-27 | — | — | WO | disclosed |
| WO-2007071585-A1 | PESTCIDAL COMPOSITIONS | BASF SE (DE) | 2007-06-28 | — | — | WO | disclosed |
| EP-0929537-A1 | TROPONYL PIPERAZINES AS SELECTIVE DOPAMINE D4 RECEPTOR LIGANDS | HOECHST MARION ROUSSEL, INC. (US) | 1999-07-21 | — | — | EP | disclosed |
| WO-1998007711-A1 | TROPONYL PIPERAZINES AS SELECTIVE DOPAMINE D4 RECEPTOR LIGANDS | HOECHST MARION ROUSSEL, INC. (US) | 1998-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10654884-B2 | Purine derivatives as CD73 inhibitors for the treatment of cancer | ENTPD5, NT5E, ENTPD1 | RAPGEF4 822/4885KDM1A 2495/4885KDM1B 3018/4885 |
| US-20200102288-A1 | WDR5 INHIBITORS AND MODULATORS | WDR5, WDR1, WDR3 | RAPGEF4 1589/4885KDM1A 167/4885KDM1B 163/4885 |
| US-20170044203-A1 | PURINE DERIVATIVES AS CD73 INHIBITORS FOR THE TREATMENT OF CANCER | ENTPD5, ENTPD1, NT5E | RAPGEF4 926/4885KDM1A 2122/4885KDM1B 2554/4885 |
| US-20230159508-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | RIPK1, RIPK2, RIPK4 | RAPGEF4 620/4885KDM1A 2716/4885KDM1B 3134/4885 |
| US-20230103791-A1 | 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS | SCN8A, SCN1A, SCN1B | RAPGEF4 2014/4885KDM1A 2193/4885KDM1B 2274/4885 |
| US-10844044-B2 | WDR5 inhibitors and modulators | WDR5, WDR1, WDR3 | RAPGEF4 1556/4885KDM1A 153/4885KDM1B 143/4885 |
| US-20100010058-A1 | Azoline Compounds for Combating Arthropod Pests | NR0B1, NR4A1, NR4A3 | RAPGEF4 1810/4885KDM1A 1026/4885KDM1B 1512/4885 |
| US-20080312085-A1 | Pesticidal Compositions | ANXA1, PRDX1, PRDX2 | RAPGEF4 2837/4885KDM1A 473/4885KDM1B 638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.